Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay
Annals of Internal Medicine · 2026-07 · 179 (7) · 958-967
DOI: 10.7326/annals-25-04689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Internal Medicine, 2026-07. Verfasst von Kaleen N Hayes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gerontology and Healthcare Research, Department of Health Services, Policy & Practice, Brown University School of Public Health, Providenc…. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Skilled Nursing Facilities, Dementia, Herpes Zoster. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Themen: Gerontologische Pflege, Demenz
Abstract (Originalsprache)
BACKGROUND: Observational studies report a protective association between herpes zoster (HZ) vaccination and dementia, but they have methodological limitations or examined a live attenuated vaccine no longer available in the United States. OBJECTIVE: Among older adults recently admitted to a skilled-nursing facility for postacute or long-term care, to estimate the association between dementia and receipt of the recombinant HZ vaccine (RZV) within 12 months of entering the facility or after discharge. DESIGN: The researchers conducted a cohort study using target trial emulation and the clone-censor-weight approach. Participants were followed for up to 4 years until the outcome of dementia, Medicare disenrollment, or death. Inverse probability of clone-censoring weights were applied to pooled logistic regression models to estimate effects. SETTING: Medicare claims linked to nursing home electronic health record (EHR) data. PARTICIPANTS: Medicare fee-for-service beneficiaries aged 66 years or older who were admitted to a skilled-nursing facility between 1 January 2017 and 31 December 2022, had linked EHR data, had no diagnosed dementia, and were eligible for RZV. INTERVENTION: Receipt of at least 1 RZV in the facility or, if discharged, by 12 months after admission versus no receipt of RZV. MEASUREMENTS: Validated dementia diagnosis and 57 baseline and time-varying covariates. RESULTS: The study cohort included 509 926 participants (mean age, 79 years); 8843 (1.73%) received at least 1 RZV dose within 12 months after admission, and of these, 87.0% received RZV after discharge. Receipt of RZV was associated with risk for dementia being 5.8 percentage points lower (95% CI, 3.9 to 7.5 percentage points lower; risk ratio, 0.76 [CI, 0.69 to 0.84]; 4-year risk, 18.8% with ≥1 RZV vs. 24.6% with no RZV). Associations were attenuated in men and those with prior live HZ vaccination. LIMITATION: Negative control analyses suggest some residual confounding. CONCLUSION: Receipt of RZV during admission to a skilled-nursing facility or within 12 months was associated with lower dementia risk. PRIMARY FUNDING SOURCE: GlaxoSmithKline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Gerontology and Healthcare Research, Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island (K.N.H., L.R.G., R.J., P.C.).
- Department of Epidemiology, College of Health Sciences, University of Delaware, Newark, Delaware (D.A.H.).
- Center for Gerontology and Healthcare Research, Department of Health Services, Policy & Practice, Brown University School of Public Health, and Transformative Health Systems Research to Improve Veteran Equity and Indepe…
- Insight Therapeutics, Norfolk, Virginia (L.H., H.E.D.).
- Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation, Providence VA Medical Center, and Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of B…
- Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation, Providence VA Medical Center; Division of Geriatrics and Palliative Medicine, Warren Alpert Medical School of Brown…
ORCID-Profile: Kaleen N Hayes, Kevin W McConeghy, Lisa Han, H Edward Davidson, Thomas A Bayer, Stefan Gravenstein
Zitieren
APA
Hayes, K. N., Harris, D. A., McConeghy, K. W., Grove, L. R., Joshi, R., Han, L., Davidson, H. E., Chachlani, P., Bayer, T. A., Singh, M., Abul, Y., DeVone, F., & Gravenstein, S. (2026). Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay. Annals of Internal Medicine, 179(7), 958-967. https://doi.org/10.7326/annals-25-04689
Vancouver
Hayes KN, Harris DA, McConeghy KW, Grove LR, Joshi R, Han L, et al. Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay. Annals of Internal Medicine. 2026;179(7):958-967. doi:10.7326/annals-25-04689
BibTeX
@article{Hayes2026,
author = {Hayes, Kaleen N and Harris, Daniel A and McConeghy, Kevin W and Grove, Lexie R and Joshi, Richa and Han, Lisa and Davidson, H Edward and Chachlani, Preeti and Bayer, Thomas A and Singh, Mriganka and Abul, Yasin and DeVone, Frank and Gravenstein, Stefan},
title = {Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay},
journal = {Annals of Internal Medicine},
year = {2026},
volume = {179},
number = {7},
pages = {958--967},
doi = {10.7326/annals-25-04689}
}
EUVIMED